Close
Additional Broadridge resources:
View our Contact Us page for additional information.
One of our sales representatives will email you about your submission.
Welcome back, {firstName lastName}.
Not {firstName}? Clear the form.
Want to speak with a sales representative?
Your sales rep submission has been received. One of our sales representatives will contact you soon.
Our representatives and specialists are ready with the solutions you need to advance your business.
Want to speak with a sales representative?
| Table Heading | |
|---|---|
| +1 800 353 0103 | North America |
| +442075513000 | EMEA |
| +65 6438 1144 | APAC |
Your sales rep submission has been received. One of our sales representatives will contact you soon.
Want to speak with a sales representative?
| Table Heading | |
|---|---|
| +1 800 353 0103 | North America |
| +442075513000 | EMEA |
| +65 6438 1144 | APAC |
Nos représentants et nos spécialistes sont prêts à vous apporter les solutions dont vous avez besoin pour faire progresser votre entreprise.
Vous voulez parler à un représentant commercial?
| Table Heading | |
|---|---|
| +1 800 353 0103 | Amérique du Nord |
| +1 905 470 2000 | Canada Markham |
| +1 416 350 0999 | Canada Toronto |
Votre soumission a été reçue. Nous communiquerons avec vous sous peu.
Vous souhaitez parler à un commercial ?
| Table Heading | |
|---|---|
| +1 800 353 0103 | Amérique du Nord |
| +1 905 470 2000 | Canada Markham |
| +1 416 350 0999 | Canada Toronto |
Two of the aspects of derivatives trade reporting that have created the most pain for both reporting firms and regulators are unique transaction identifiers (UTIs) and Legal Entity Identifiers (LEIs). They also have the potential to create difficulties for market participants in Securities Financing transaction reporting under SFTR. However, there are benefits for firms who embrace the opportunities created by using LEIs and UTIs. This article examines the long term potential for how changes and innovations such as LEIs and UTIs could drive the overall improvement of infrastructure, processes and data quality.
Martin Walker is the head of product management for Broadridge’s Securities Finance and Collateral Management division. Former roles include Global Head of Securities Finance and Treasury IT at Dresdner Kleinwort and Global Head of Prime Brokerage Technology at RBS Markets. He has also worked as a consultant and researcher in capital markets with several papers published. He contributed to the new book “Evidence-Based Management – How to Use Evidence to Make Better Organizational Decisions” and his first book on Capital Markets infrastructure; Front to Back was published in 2018. He has an MSc in Computing Science from Imperial College, London and a BSc in Economics from the London School of Economics. He is also a fellow of the Center for Evidence-based Management.
